• What Kind Of Shareholders Own The Green Organic Dutchman Holdings Ltd. (TSE:TGOD)?
    Simply Wall St.

    What Kind Of Shareholders Own The Green Organic Dutchman Holdings Ltd. (TSE:TGOD)?

    A look at the shareholders of The Green Organic Dutchman Holdings Ltd. (TSE:TGOD) can tell us which group is most...

  • Aurora Cannabis Inc. (ACB) Flat As Market Gains: What You Should Know

    Aurora Cannabis Inc. (ACB) Flat As Market Gains: What You Should Know

    In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $5.27, marking no change from the previous day.

  • Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know

    Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know

    Cronos Group (CRON) closed the most recent trading day at $10.96, moving -1.7% from the previous trading session.

  • Benzinga

    The Latest On Juul: Congress Threatens Subpoena; China, India Halt Sales

    A House subcommittee responsible for overseeing consumer product investigations looked into Juul's practices in June and said in a letter delivered to the company that it has not fully complied with requests, CNBC reported. Lawmakers were interested in viewing a list of schools who financially benefited from an anti-vaping curriculum and details related to Altria's 35% stake. "Those documents have not been produced," Subcommittee Chairman Raja Krishnamoorthi, D-Illinois, was quoted by CNBC as saying in an MSNBC interview.

  • CannTrust (CTST): A Reality Check

    CannTrust (CTST): A Reality Check

    The original investor hope surrounding the regulatory issues at CannTrust Holdings (NYSE:CTST) was a quick solution that got the company back into business selling cannabis. The problem all along was that the news continuously got worst for the company. The final straw is the suspension of their license to produce and sell cannabis by Health Canada.As a result, investor sentiment is negative, with individual portfolios in the TipRanks database showing a net pullback from CTST.Not Much Left Back on July 8, CannTrust announced that Health Canada found the Canadian cannabis company to be in non-compliance with an audit conducted by the regulatory body. Specifically, the company and executive management team had hidden the growing of cannabis in non-licensed rooms.Originally, CannTrust presented the idea that Health Canada would rule on tests of the cannabis from these unlicensed sources within 10 to 12 business days or somewhere around mid-July. The reality is that the Canadian regulatory body only now ruled on September 17 to pull the license of CannTrust.The company reported this morning the receipt of a Notice of License Suspension under section 64(1) of the Cannabis Act (Canada). CannTrust is not allowed to produce or sell cannabis while the license is suspended. The only allowed operations are the cultivating and harvesting of existing plants in the ground.The company had already fired the CEO and withheld sales and shipment of cannabis products while awaiting the Health Canada review. CannTrust hasn’t sold products going on three months leading to massive ongoing losses with no clear path to returning to business anytime soon, if ever.Mounting Costs For Q1, CannTrust had operating costs of about C$10 million in the quarter before counting C$2.2 million in selling and shipping costs. The company will incur most of these costs going forward before cutting employees.This amount doesn’t factor in expected growth in the employee base for Q2 since CannTrust hasn’t reported the June quarter results yet. In addition, the cannabis company had about C$9.1 million in production costs for the March quarter that will be occurred in the current quarter with the company still growing cannabis in the anticipation of obtaining Health Canada approval to return to selling product.The company burned C$19.0 million in cash during the March quarter and one can easily see those amounts repeated and exceeded in both Q2 and Q3. The good news is that the company raised $170 million back before the regulatory issues to supplement about $30 million on the balance sheet at the end of March. The company has the cash to fund these ongoing losses for an extended period.A big worry is that shareholder lawsuits could wipe out the remaining cash. In addition, what made the stock appealing was the additional capacity expected to come online considering the move to beat the market to growing cannabis outdoor. CannTrust has lost the first mover advantage here.Consensus VerdictUltimately, the word on the Street points to a sidelined majority on CannTrust. In the last three months, the embattled cannabis stock has landed 3 ‘buy’ ratings vs. 4 ‘hold’ and 2 'sell' ratings. (See CTST's price targets and analyst ratings on TipRanks)TakeawayThe key investor takeaway is that once CannTrust failed the Health Canada audit, the stock was placed on a watch list due to intriguing value if the company was able to quickly regain compliance. The problem all along was the uncertainty surrounding the real details of the audit failure and how the regulatory body would actually act.The best outcome here is a likely sale of the company or the cannabis production assets, but any investor is gambling to expect gains from the current stock price near $1.25. Any deal could easily be a take under considering the operating losses and legal uncertainties.Disclosure: No position.

  • Barrons.com

    Don’t Buy Canopy Growth Stock. The Marijuana Company Is About to Lose a Ton of Money, Analyst Says

    Canadian marijuana producer Canopy Growth has loads of cash and an early start, as prohibitions fall around the world. But at $28 per share, Canopy stock is expensive, an analyst said.

  • 5 Stocks You Shouldn’t Hold Through the Next Recession

    5 Stocks You Shouldn’t Hold Through the Next Recession

    It's easy to predict that a recession will come eventually. They always do. The trick is in the when - and even the most experienced experts take a lot of swings without making contact.But more strategists and economists are increasing their odds of a forthcoming recession. An August survey by the National Association for Business Economics showed that three of four economists expect a recession by 2021. It could come sooner than that. Also in August, Bank of America analysts said there's a greater-than-30% chance of a recession within 12 months. In a June interview, economist Gary Shilling said, "I think we're probably already in a recession."There are plenty of potential catalysts. Numerous international central banks are easing their policies to battle slowing economic growth. America's Federal Reserve is no exception - it just announced the second cut in its benchmark interest rate this year. The U.S.-China trade war is exacerbating things, with a salvo of tariffs weighing on consumers here and abroad. This has been reflected in the Treasury yield curve, which has inverted several times in 2019 - a recessionary warning sign.Don't look to these five stocks for recession protection. Many businesses surely will feel the pinch of an economic pullback. But these five better-known names - while fine companies in some respects - have issues such as high debt levels and struggling growth despite the economic expansion that might make a downturn more painful for them than others. SEE ALSO: The Pros Say No: 7 Large-Cap Stocks to Sell or Avoid

  • Is Tilray Stock’s Crushing Bear Market Finally Over?

    Is Tilray Stock’s Crushing Bear Market Finally Over?

    Tilray (NASDAQ:TLRY), like so many marijuana stocks, is having a terrible year. Yes, some traders like to make fun of anyone that bought Tilray stock near its $300/share peak. But don't forget that as recently as this January, Tilray stock still traded for as much as $100 per share. This year alone, shares have lost more than half their remaining value.Source: Jarretera / Shutterstock.com That shouldn't come as a surprise. As I explained in May, the company was doing better on earnings but the supply growth from other producers overwhelmed Tilray's progress. That's been a valid concern so far. TLRY stock has continued to sink as the oversupply in the Canadian marijuana market has further intensified.The worst may finally be over, however. Tilray stock has rebounded more than 20% from its 52-week low since the start of September.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Momentum Stocks to Buy On the Dip Is Tilray ready to rally again? Tilray's Growth Strategy Seems ReasonableDespite the punishing decline in Tilray's stock price, management hasn't panicked. As I explained in that previous article, Tilray CEO Brendan Kennedy has focused on disciplined supply growth at a reasonable price. Tilray's deals, such as buying Manitoba Harvest came at affordable prices rather than paying big bucks as firms like Canopy Growth (NYSE:CGC) have done with some of their acquisitions.Tilray has also wisely used convertible bonds to raise funds. The convert feature is now way out of the money, ensuring that shareholders won't be diluted unless Tilray shares go on a monster run. This was a savvy way to raise nearly half a billion in funds without hitting TLRY stock owners with much dilution.Finally, while the international market hasn't taken off that quickly, Tilray has a shot there as well. The company is building out its facilities in Portugal -- again at a reasonable build-out cost. Still Hasn't Reached Critical MassTilray stock bears, on the other hand, continue to question Tilray's prospects. While the company certainly has avoided some of the excesses of its rivals, at the end of the day you need revenues and profits to justify your share price.And Tilray simply doesn't have much of either. Tilray's market cap, even with the stock at just $30, is still almost $3 billion. That's a huge valuation for a company that has produced less than $100 million in revenues over the last year. If revenues reach $200 million over the next year or two and Tilray manages to maintain a still robust 10x price/sales ratio, that'd imply an additional 33% downside on TLRY stock to around $20/share.Also, despite the small revenue base, Tilray has a ton of product lines. With the addition of Manitoba Harvest, it now has foods and supplements in addition to the more standard fare. And Tilray has international operations in a variety of countries. Yet, it hasn't added up to a critical mass that can deliver sustainable profits just yet. Like with Aurora (NYSE:ACB), Tilray has a lot of irons in the fire, but there's no sign that any particular thing is heating up just yet. CannTrust Reminds Us Of Dangers In The Cannabis IndustryWhile Tilray stock has enjoyed a welcome rebound, the industry isn't out of the woods yet. The huge supply and demand imbalance continues to weigh painfully on the sector. And that's not all. Regulatory risk remains a major concern.Tuesday brought us a fresh reminder on that front. CannTrust (NYSE:CTST) stock plunged another 14% on the day. CannTrust hit new all-time lows after admitting that Health Canada had suspended the company's license to produce and sell marijuana. It's a suspension, rather than a full revocation of their operating license. Still, it was a huge blow to the company's already damaged credibility.The license suspension on its own shouldn't come as a huge surprise. As InvestorPlace's Josh Enomoto recently wrote, CannTrust suffered two major scandals. The first involved illegal growing operations hidden with false walls. CannTrust fired its CEO with cause, along with other top employees, as a result. The company also somehow had black market seeds get mixed into its inventory.Adding it all up, CannTrust stock is now down a shocking 90% from where it traded earlier in 2019. That's a nearly total wipeout for a New York Stock Exchange-listed company. While there's nothing that dramatic going on with Tilray from a scandal point of view, CannTrust's collapse serves as a fitting reminder that this is a new industry that will have tons of growing pains.Also, it's worth noting that marijuana companies have started getting more traction in mainstream stock indexes and associated ETFs. However, the index operators will now kick CannTrust stock out of the primary Canadian stock index and related ETFs, and other fund operators may be slower to include pot stocks like Tilray in their funds as a result of this incident. Tilray Stock VerdictTilray has much better management than CannTrust, thank goodness. But that doesn't mean that is time to get too excited about the recent rebound in the TLRY stock price.The cannabis industry is continuing to face massive growing pains. There will be winners eventually. But more companies will end up like CannTrust as well. The industry is young and a lot of competition has to fall by the wayside for the survivors to prosper. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Tilray, without a major partner, hasn't yet proven that it will be able to be one of the industry's eventual winners. For now, Cronos (NASDAQ:CRON) and Canopy, with their major backers, might be a safer choice until the industry's slump ends.At the time of this writing, Ian Bezek had no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars * 5 Stocks to Buy With Great Charts * 5 Goldman Sachs Stocks to Buy with Over 20% Upside Potential The post Is Tilray Stock's Crushing Bear Market Finally Over? appeared first on InvestorPlace.

  • Top Analyst Reports for AbbVie, Union Pacific & CSX

    Top Analyst Reports for AbbVie, Union Pacific & CSX

    Top Analyst Reports for AbbVie, Union Pacific & CSX

  • Benzinga

    Cannabis Deals And M&A Picking Up Steam Again

    The Viridian Cannabis Deal Tracker is an information service that monitors capital raise and M&A activity in the legal cannabis industry. Analyzing within 12 key industry sectors, the Viridian Cannabis Deal Tracker provides cannabis companies, investors, and acquirers with the data, trends, and intelligence they need to make informed decisions regarding deal valuations, terms, and structures. Since its inception, the Viridian Cannabis Deal Tracker has tracked and analyzed more than 2,400 capital raises totaling over $29 billion as well as more than 800 M&A transactions.

  • 3 Cannabis Stocks to Buy Today

    3 Cannabis Stocks to Buy Today

    As many investors know, hype doesn't equal profits when it comes to growing a portfolio in cannabis stocks. Having said that, let's look at Innovative Industrial Properties (NYSE:IIPR), Scotts Miracle-Gro (NYSE:SMG) and Hexo (NYSE:HEXO) in order to avoid the buzz and cultivate better-looking possibilities off and on the price chart. Let me explain.Cannabis stocks. The market's potential is massive to say the least. But for those that have taken stakes in the group's most popular names such as Canada's top producer Canopy Growth (NYSE:CGC), former capitalization top dog Tilray (NASDAQ:TLRY) or Cronos (NASDAQ:CRON), losses have likely followed.Without getting too deep into the minutiae, early enthusiasm and momentum with most cannabis investments has adjusted to today's more difficult realities. Cannabis stocks face massive layers of regulatory red tape as they attempt to tap into new markets. And many of these companies are up to their eyeballs in debt while vying to be competitive.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Eventually, there will be winners among cannabis producers. And for those investors that hang on, the returns on the right pick could be enormous. I get it. At the same time, buying the proverbial picks-and-shovel plays and the companies already quietly making money for investors, off and on the price charts, makes for an even stronger blend of exposure to cannabis stocks. Cannabis Stocks Buy: Hexo (HEXO)Hexo is our first "buy" recommendation. HEXO stock is also the most speculative of our three cannabis stocks to buy. The company is looking to cash in on the niche edibles and cannabis-infused beverages market, and has stronger odds of success courtesy of its partnership with Molson Coors (NYSE:TAP) which allows it access to the beverage giant's many resources.On the price chart, HEXO stock is unique among its peer group. Despite this year's steep correction in cannabis stocks, shares of Hexo have maintained a weekly uptrend. The last few weeks have been spent trying to rally out of a well-supported, small double-bottom pattern.With pattern confirmation in hand and a supportive-looking stochastics setup, my recommendation in HEXO is to buy shares today. I won't put a price tag on the upside potential of this more speculative play. But placing an exit below support, if required, is smart business. Scotts Miracle-Gro (SMG)Scotts Miracle-Gro is the second of our stocks to buy. If you've ever been in a Home Depot (NYSE:HD) or Lowe's (NYSE:LOW) -- or mowed a lawn for that matter -- SMG stock is familiar with its lawn and gardening products. Scotts is also profitable, offers a dividend of 2.3% and happens to nicely positioned within the cannabis industry as its largest hydroponics supplier.Technically, today's investors are able to buy SMG stock as it pulls back into a high consolidation pattern. The price action has taken on the characteristics of a high handle formation after shares broke out of a large cup-shaped base to new highs, but began to retreat following a gain of around 8%. * 7 Momentum Stocks to Buy On the Dip With SMG stock just now registering an oversold stochastics condition, my advice is to put shares on your radar to purchase on a second move back above the prior high and above the cup breakout level of $105.23. Place an initial stop-loss below $99. Innovative Industrial Properties (IIPR)Innovative Industrial Properties is the last of our three cannabis stock buys. IIPR stock is a landlord for many of the sector's producers. Like SMG stock, IIPR is profitable and as a real estate investment trust, investors are paid regular income of 3.4%. But please, don't think of IIPR as a widows-and-orphans investment like Coca-Cola (NYSE:KO). These shares are volatile.Currently, IIPR stock's aggressive profile has taken shares out of a symmetrical triangle pattern and into a deep correction of around 40% at the recent low. Again, this cannabis stock is not for the faint of heart.The good news today is that shares are oversold and have signaled a bullish stochastics crossover. And with IIPR confirming a weekly candlestick reversal pattern after loosely testing key Fibonacci support, this cannabis stock is ripe for the picking in conjunction with a blended stop-loss below $80.90.Investment accounts under Christopher Tyler's management do not currently own positions in any securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional options-based strategies and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars * 5 Stocks to Buy With Great Charts * 5 Goldman Sachs Stocks to Buy with Over 20% Upside Potential The post 3 Cannabis Stocks to Buy Today appeared first on InvestorPlace.

  • Benzinga

    This Cannabis ETF Just Dodged Another CannTrust Bullet

    Just when it seemed it couldn’t get any worse for CannTrust Holdings Inc (NYSE: CTST) (TSE:TRST), we learned Health Canada has suspended its license to produce and sell cannabis. While suspended going forward, CannTrust will be allowed to complete the cultivation, harvest and sale of existing lots. While many are getting burned, The Cannabis ETF (NYSE: THCX), the fund backed by Jon Najarian and Pete Najarian, seems to have dodged a bullet.

  • Vaping-Related Deaths: Anxiety Rises for Cannabis Stocks
    Market Realist

    Vaping-Related Deaths: Anxiety Rises for Cannabis Stocks

    Vaping has become a burgeoning health concern, as the seventh vaping-related death recently occurred in California. How are cannabis companies affected?

  • MarketWatch

    Canopy Growth stock gains again; Oppenheimer initiates at 'perform' with no price target

    The U.S.-listed shares of Canopy Growth Corp. edged up 0.3% toward a fourth straight gain in midday trading Wednesday, although Oppenheimer analyst Rupesh Parikh initiated coverage of the Canada-based cannabis company with a not-so-enthusiastic "perform" rating and no price target. Parikh said that he believes Canopy is "best positioned" to capitalize on the global cannabis market over time, given its first-mover advantage, investments in key geographies, such as the U.S., Canada and Europe, partnership with Constellation Brands Inc. and the most capital of any cannabis player. "However, shorter-term, we believe a full valuation, lofty [Wall] Street expectations, the potential for losses to persist and regulatory delays hamper the case for outperformance," Parikh wrote in a note to clients. The regulatory delays refers to delays regarding use of CBD (cannabinoids) in the U.S. Of the 24 analysts surveyed by FactSet, nine have the equivalent of hold, 14 have the equivalent of buy and one has the equivalent of sell. The stock has now gained 5.9% year to date, while the ETFMG Alternative Harvest ETF has lost 4.7% and the S&P 500 has rallied 19.5%.

  • Are Insiders Selling New Age Beverages Corporation (NASDAQ:NBEV) Stock?
    Simply Wall St.

    Are Insiders Selling New Age Beverages Corporation (NASDAQ:NBEV) Stock?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • Bloomberg

    Wrecking Purdue Pharma Won’t Help Opioid Victims

    (Bloomberg Opinion) -- There are few quotations that have stuck with me over the years like the one delivered by the anti-tobacco scientist Stanton Glanz back in 2006, when I was writing an article about Altria Group Inc. Asked what his ultimate goal was, he didn’t say it was to get people to stop smoking. He said it was “to destroy the tobacco companies.”I thought of that line on Monday, the day after Purdue Pharma LP filed for bankruptcy, and the day ahead of the first court hearing before the respected U.S. Bankruptcy Court Judge Robert Drain, in White Plains, N.Y.The filing was inevitable: No company can withstand over 2,600 lawsuits from states, counties, cities and Native American tribes all across the country.What was not inevitable was Purdue’s proposed solution. As part of its bankruptcy filing, Purdue unveiled a settlement proposal that would set up a trust to give cash to those affected by the opioid crisis it helped trigger with its primary product, the painkiller OxyContin. The money, which Purdue estimated at around $10 billion, would come from the company’s present and future profits, as well as $3 billion from Purdue’s owners, heirs of founders Arthur, Mortimer and Raymond Sackler. Some 24 states were backing the settlement, along with five territories and over 1,000 counties. But other states are opposing the settlement, including Massachusetts. In an op-ed article in The Washington Post on Monday, Massachusetts Attorney General Maura Healey explained why. The proposed settlement, she wrote, “doesn’t hold the company or its owners accountable.” After documenting Purdue’s undeniable role in the crisis — “We uncovered a scheme to get more patients on opioids, at higher doses, for longer periods of time,” she wrote, even as the Sacklers were pocketing billions — she declared: “Accountability means making the Sackler family reach into their own pockets. It means telling the whole truth. It means shutting down Purdue for good.”That’s just crazy. The idea that shutting down Purdue will somehow be a societal good is exactly like saying that destroying tobacco companies is more important than getting people to stop smoking. The goal should be to provide money that government entities can use to combat the crisis. It should be to develop pain-relief drugs that are abuse resistant. It should be to find ways to manage severe pain without relying on drugs that addict and kill. Shutting down Purdue might give some attorneys general a notch on their belts, but it won’t help bring the opioid crisis to an end.At the hearing in White Plains on Tuesday — a sedate affair that mainly established the rules under which Purdue would continue to operate while in bankruptcy — the company’s lead attorney, Marshall Huebner of Davis, Polk & Wardwell, outlined the Purdue plan.A trust would be set up, controlled by the plaintiffs, that would dole out money to communities and individuals who had legitimate claims of being harmed by opioids. The trust would take control of Purdue, meaning that those who are now suing Purdue would effectively own the company. It would continue to manufacture OxyContin, but the owners would also be able to direct the company towards developing drugs to counteract opioid addiction. Meanwhile, Purdue profits would be sent to the trust.In the near term, Huebner said, the company’s goal was maximizing and preserving its value. That meant stopping the millions it was spending on lawyers — and the millions more it would be spending if it had to start trying cases. It meant retaining scientists and other key employees who were wondering whether they should jump ship. He described what Purdue was doing as “radically de-risking the situation,” in the sense that those suing the company were being guaranteed every penny Purdue could generate without the risk of losing at trial. Purdue, meanwhile, was eliminating the risk of being put out of business through litigation, which wouldn’t leave anywhere near the amount of money the plaintiffs were now going to get.“Purdue is not shielding itself from these claimants,” Huebner said. “It is giving itself to these claimants without them ever having to prevail in the litigation.” He added: “It is very much the best case for the country. Pursuing cases outside Chapter 11 benefits no one.”The real bone of contention between those who back the settlement and those who oppose it isn’t so much what will happen to Purdue as it is what will happen to the Sacklers. Huebner made much of the fact that the family would be selling another pharmaceutical company it owns to help raise the $3 billion. But that is exactly what galls critics like Healey: selling a company to raise money is different from taking money out of your pocket and handing it over to the people who are suing you.At the hearing, Purdue’s lawyers went out of their way to assure the court and the critics that the company was disassociating itself as much as possible from the Sacklers. No Sackler family member remained on the board. No Sacklers would get their legal fees paid by the company. No Sacklers would get any of the retention bonuses and other money the company was spending to hold onto key employees. Be that as it may, it seems pretty clear that critics like Healey won’t be satisfied unless the settlement inflicts more pain on the family.Right now, the bankruptcy has stopped all litigation against Purdue, including from the government entities that are opposing the settlement. Over the next few months, Judge Drain will have to decide whether the lawsuits brought by those who have not agreed to settle can continue. As Bloomberg News pointed out on Tuesday, while Drain could put all litigation on hold, the law tends to favor attorneys general who want to keep suing. If he allows the suits to continue, the settlement will fall apart. As the company put it in court papers, “Absent this protection [from lawsuits], the fundamental goal of this or any bankruptcy will have been thwarted.”A better approach would be to encourage the various government entities to forge a settlement with Purdue that excluded the Sacklers. Then they could continue suing family members, or craft a different settlement with them that took away a significant portion of the $13 billion they are said to be worth. Now that there are no Sacklers on the Purdue board, this strikes me as reasonably realistic.In 1981, Johns Manville, an insulation and roofing manufacturer facing thousands of lawsuits for covering up the dangers of asbestos, filed for bankruptcy. It was the first company to employ the technique Purdue hopes to use: It set up the Manville Trust and seeded it with 75 percent of the company stock. The trust pays out claims to this day. (Johns Manville, no longer associated with the trust, is now owned by Berkshire Hathaway.)Here’s the kicker, though. It took seven years for Johns Manville to emerge from bankruptcy and for the Manville Trust to be established. Even then, tens of thousands of people who had asbestos-related cancer had to wait another three, four or five years to get any compensation. And they received only pennies on the dollar.The entities affected by the opioid crisis — whether states, cities, tribes or individuals — can’t wait that long to get relief. They need it now. The settlement that was negotiated between Purdue and the plaintiffs will get them that money. That’s enough reason the settlement on the table is the best way forward, even if it doesn’t satisfy the soul.To contact the author of this story: Joe Nocera at jnocera3@bloomberg.netTo contact the editor responsible for this story: Jonathan Landman at jlandman4@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Joe Nocera is a Bloomberg Opinion columnist covering business. He has written business columns for Esquire, GQ and the New York Times, and is the former editorial director of Fortune. His latest project is the Bloomberg-Wondery podcast "The Shrink Next Door."For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • Barrons.com

    A Philip Morris and Altria Deal Looks More Likely, Analyst Says

    Markets may not be thrilled with the idea of Altria Group and Philip Morris International recombining, but Citigroup argues that a merger between the tobacco giants is looking more likely.

  • Is Canopy Growth (TSE:WEED) Weighed On By Its Debt Load?
    Simply Wall St.

    Is Canopy Growth (TSE:WEED) Weighed On By Its Debt Load?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • Market Exclusive

    Cannabis Stock News Daily Roundup September 18

    Supreme Cannabis (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) has reported its financial results for the fourth quarter and fiscal year ended June 30, 2019. Revenue was C$19.01 million, up from C$3.55 million for the fourth quarter of 2018. Net loss for the quatre was C$421,000, compared to a profit of C$234,000 for the same period last […]The post Cannabis Stock News Daily Roundup September 18 appeared first on Market Exclusive.

  • Investing.com

    StockBeat: Altria Shares Hit 52-Week Low After India Bans E-Cigarettes

    Investing.com - Shares of tobacco company Altria Group (NYSE:MO) set a new 52-week low of $40.82 Wednesday after India announced a ban on e-cigarettes as a global backlash against vaping gathers pace.

  • Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line

    Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line

    Zimmer Biomet's (ZBH) JuggerStitch claims to offer a less invasive, all-suture, knotless approach to meniscal repair procedures.

  • Tide Turns Against Vaping as India Bans Sales, China Sites Pull Juul

    Tide Turns Against Vaping as India Bans Sales, China Sites Pull Juul

    (Bloomberg) -- India became the latest country to ban electronic cigarettes only days after Juul Labs Inc.’s products vanished from online Chinese marketplaces, a sign Asian nations may be no refuge for the industry from an escalating crackdown in the U.S.India’s government announced an executive order Wednesday banning the sale and production of all e-cigarettes, echoing growing concerns worldwide over health risks associated with the smokeless nicotine devices popular with teenagers.“Why are we debating if it’s more harmful or less? It is harmful. It is addictive,” said Preeti Sudan, India’s health secretary. “The entire next generation will be going down the drain if we don’t control it now.”Originally touted as a safer alternative to wean people off cigarettes, e-cigarettes have come under widespread attack in the U.S., especially for their appeal among youth. India’s decision follows similar prohibitions in about 27 other countries including Australia, Singapore and Brazil and comes on the heels of halted online sales of Juul’s products in China, the world’s largest tobacco market.‘Strong’ ActionDespite increasing global curbs on vaping, some nations view e-cigarettes as viable alternatives to smoking, a leading cause of preventable death. And though cigarette companies are getting into the electronic nicotine-delivery business -- including most notably a nearly $13 billion investment in Juul by Marlboro maker Altria Group Inc. -- a vaping health scare could cause sales of the tobacco giants’ most important products to jump.Shares of cigarette makers in India gained on news of the ban.U.S. President Donald Trump has vowed to “do something very, very strong” after the recent outbreak of a mysterious lung disease linked to vaping that has killed six people in the U.S. and afflicted hundreds of others. Lawmakers in the U.S. are also investigating the marketing of Juul, America’s top-selling e-cigarette brand.U.S. Representative Raja Krishnamoorthi, an Illinois Democrat, told Juul Chief Executive Officer Kevin Burns in a letter dated Tuesday that the company had failed to produce all the documents requested by a House Oversight Committee and that further delay could result in the company receiving a subpoena.Juul only started selling its nicotine vaporizers online in China last week. Its official online stores disappeared on Alibaba Group Holding Ltd.’s Tmall and JD.com Inc. by Tuesday, prompting speculation that official action may be on the way.Juul wasn’t given a reason for why its products were pulled, according to a person familiar with the matter, but said in a statement it wants to make them available again.No Reasons GivenThe latest developments in India and China come as a blow to vaping companies that were setting their sights on Asia, where 65% of the world’s cigarettes are sold, as increased pressure in the U.S. forces them to look for growth elsewhere. India alone has 266.8 million tobacco users, according to a WHO factsheet.It isn’t clear if China plans to ban or enforce stricter scrutiny of e-cigarettes or vaping devices. The country’s National Health Commission -- a body responsible for health and sanitation -- announced it was devising legislation for such products in July, arguing the “hazards of e-cigarettes should be highly valued.”The Chinese health commission also said labels describing nicotine concentration on many such products are vague, and can lead to excessive consumption by users.Michael R. Bloomberg, the founder and majority owner of Bloomberg News parent Bloomberg LP, has campaigned and given money in support of a ban on flavored e-cigarettes and tobacco.Some nations, however, view vaping as a lesser evil than smoking.Public health officials in the U.K., the biggest market in Europe for the products, endorse vaping as a way to wean people off smoking -- the prevailing view across Europe, where authorities are more sanguine about the effects of vaping.E-cigarettes allow users to satisfy their cravings by inhaling vaporized nicotine rather than tobacco smoke. Their popularity has soared in recent years driven by candy-like flavorings, sleek devices and savvy marketing.The U.S. Surgeon General called it an “epidemic,” after Health and Human Services Secretary Alex Azar told reporters that 5 million American kids said they’ve vaped this year. The Food and Drug Administration has been investigating the safety of e-cigarettes after reports of seizures.(Updates with U.S. lawmaker’s letter to Juul Labs in eighth paragraph.)\--With assistance from Carolynn Look and Shruti Srivastava.To contact the reporters on this story: Ari Altstedter in Mumbai at aaltstedter@bloomberg.net;Bibhudatta Pradhan in New Delhi at bpradhan@bloomberg.netTo contact the editors responsible for this story: Rachel Chang at wchang98@bloomberg.net, Bhuma Shrivastava, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.